New antibiotic development: The need versus the costs

The Lancet Infectious Diseases

Volumn 16, Issue 4, 2016, Pages 386-387

  Welte, Tobias ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ERYTHROMYCIN; KETOLIDE; LACTAM; MACROLIDE; MOXIFLOXACIN; PIKROMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOLITHROMYCIN; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT;

BACTERICIDAL ACTIVITY; BIOFILM; BRONCHIECTASIS; CHRONIC GASTRITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DRUG COST; DRUG DEVELOPMENT; DUODENUM ULCER; GENE CONTROL; GERMANY; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; LEGIONELLA; MYCOPLASMA; MYCOPLASMA PNEUMONIA; NOTE; PEPTOCLOSTRIDIUM DIFFICILE; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; STOMACH DISEASE; STOMACH ULCER; TREATMENT DURATION; HUMAN;

ANTI-BACTERIAL AGENTS; HUMANS;

EID: 84961408972     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)00068-2     Document Type: Note

References (11)

1. McFarlane A, Sligl W The value of macrolide-based regimens for community-acquired pneumonia. Curr Infect Dis Rep 2015, 17:50.
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(suppl 2):S27-S72.
3. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections-summary. Clin Microbiol Infect 2011, 17(suppl 6):1-24. Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases.
4. Daneman N, McGeer A, Green K, Low DE Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006, 43:432-438. Toronto Invasive Bacterial Diseases Network.
5. Cilloniz C, Albert RK, Liapikou A, et al. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia. Am J Respir Crit Care Med 2015, 191:1265-1272.
6. Principi N, Esposito S Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother 2013, 68:506-511.
7. Barrera CM, Mykietiuk A, Metev H, et al. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITARE-ORAL). Lancet Infect Dis 2016, for the SOLITAIRE-ORAL Pneumonia Team, published online Feb 4. http://dx.doi.org/10.1016/S1473-3099(16)00017-7.
8. Oldach D, Clark K, Schranz J, et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother 2013, 57:2526-2534.
9. Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015, 372:1312-1323.
10. Welte T, Torres A, Nathwani D Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012, 67:71-79.
11. Li JZ, Winston LG, Moore DH, et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007, 120:783-790.